BioDlink International Company Limited (Stock Code: 1875) issued an announcement on January 19, 2026, regarding the voluntary conditional cash offer jointly made by WuXi XDC Cayman Inc. and WuXi Biologics (Cayman) Inc. The announcement follows a previous joint announcement dated January 14, 2026.

BioDlink International appointed Grand Moore Capital Limited, licensed to carry out Type 1 and Type 6 regulated activities under the Securities and Futures Ordinance, as the Independent Financial Adviser to the Independent Board Committee. The adviser will focus on determining whether the offer terms are fair and reasonable and providing guidance on acceptance of the offers. This appointment has been approved by the Independent Board Committee in accordance with relevant regulations.

The letter of advice from the Independent Financial Adviser will be included in a Composite Document, which is expected to provide shareholders and option holders with more details. The conditions for completion of the offers could be subject to satisfaction or waiver, and there is no guarantee that they will become unconditional or be completed. Shareholders, option holders, and investors are advised to review the Composite Document and to exercise caution in dealing in the securities of the company.

As stated in the announcement, the directors accept full responsibility for the accuracy of the information contained therein. The board of directors of BioDlink International comprises one executive director, one non-executive director, and three independent non-executive directors.